Cationic Biodegradable Polymer Compositions of Biomimetic Particles including Artificial Antigen Presenting Cells

Unmet Need
Over the past decade, a myriad of immune cell therapies based on the infusion of allogeneic immune cells into patients have been tested and progressed in clinical applications. Despite continual advances, immune cell therapy via antigen presenting cells is relatively expensive and time consuming, so biomimetic materials have been applied to develop artificial therapies. Artificial antigen presenting cells (aAPCs) have gained significant interest in the scientific community, and novel methods to optimize their efficacy and use are in high demand.
Technology Overview
A new form of biomimetic particles, showing improved performance in vitro over the traditional PLGA particles, have been developed and characterized. These new hybrid particles are cationic biodegradable polymer compositions of artificial antigen presenting cells. The particles stimulate T cell responses at much lower dosage (10-100 times lower) than traditional PLGA counterparts. In addition, the hybrid particles have shown higher protein selection and an increased stimulatory potential. With increased surface protein adsorption and lower dosage needed, this method improves results while simultaneously lowering cost.
Stage of Development
In vivo and In vitro studies have been conducted.
Publications
Meyer et al., HHS Public Access January 2015.

 

Category(s):